Endoscopic versus laparoscopic treatment for choledocholithiasis: a prospective randomized controlled trial

Authors
Javier Ernesto Barreras González, Rafael Torres Peña, Julián Ruiz Torres, Miguel Ángel Martínez Alfonso, Raúl Brizuela Quintanilla, Maricela Morera Pérez

Institution
Department of Laparoscopic and Endoscopic Surgery, National Center for Minimally Invasive Surgery, Havana Medical University, Havana, Cuba.

Background and study aims:
Overall, 5% to 15% of patients undergoing cholecystectomy for cholelithiasis have concomitant bile duct stones, and the incidence of choledocholithiasis increases with age. There is no clear consensus on the best therapeutic approach (endoscopic versus surgical).

Patients and methods:
A prospective randomized controlled clinical trial was performed to compare three treatment options for patients with choledocholithiasis at the National Center for Minimally Invasive Surgery in Havana, Cuba from November 2007 to November 2011. The patients were randomized in three groups. Group I: patients who underwent intraoperative cholangiography (IOC) to confirm the choledocholithiasis followed by laparoscopic cholecystectomy (LC) associated with intraoperative endoscopic retrograde cholangiopancreatography (ERCP), group II: patients who underwent preoperative ERCP followed by LC during the same hospital admission and group III: patients who underwent IOC to confirm the choledocholithiasis followed by LC associated with laparoscopic common bile duct exploration (LCBDE).

Results:
A total of 300 patients with suspected choledocholithiasis were included in the trial and were randomized. As a result, a total of 134 patients were diagnosed with the presence of choledocholithiasis and treated during the study period. There were no significant differences in success rates of ductal stone clearance, but retained stone, postoperative complications and length of hospital stay were better in group I.

Conclusions:
Intraoperative ERCP/ES shows a higher rate of common bile duct stones clearance, a shorter hospital stay, and lower morbidity, but further research with a larger study population is necessary to determine the additional benefits of this procedure. The results to date suggests that in appropriate patients, single-stage treatments are the best options.

Introduction
Overall, 5% to 15% of patients undergoing cholecystectomy for cholelithiasis have concomitant bile duct stones, and a small percentage of patients will develop common duct stones after cholecystectomy.[1] Incidence of choledocholithiasis increases with age. About 20% to 25% of patients older than age 60 have symptomatic gallstones have stones in the common bile duct and in the gallbladder [1,2].

Thus, bile duct stones and their management constitute an important clinical problem. The primary goal in management of choledocholithiasis is to obtain complete clearance of the common duct and cholecystectomy, when indicated [1,2]. Options for management of common bile duct stones (CBDS) are increasing with development of new technologies for diagnosis and treatment. Management of symptomatic or incidentally discovered choledocholithiasis is still controversial. There is no clear consensus on the best therapeutic approach (endoscopic versus surgical)[3–7]. Preoperative endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES) are safe and effective options for removing CBDS in most cases, but even when clinical, biochemical, and ultrasound criteria are used, only 10% to 60% of patients will have stones on ERCP. As a result, far too many unnecessary ERCP are being performed [8]. In fact, one of the best preventive measures to reduce ERCP complications is to not perform it if it is unnecessary.

Laparoscopic surgery of CBDS was introduced over 15 years ago and various surgical groups have shown that it has a high success rate [9,10] and is just as efficient and safe as preoperative or postoperative ERCP associated with laparoscopic cholecystectomy (LC), thereby avoiding the need to perform additional procedures [11]. Nevertheless, there is no clear consensus on the best therapeutic approach (endoscopic versus surgical) [3–7].
less, its technical difficulties, long and difficult learning curve and the need for the allocation of technical resources (high-quality fluoroscopy and choledochoscopes), which are not available at many operating theaters, has curtailed its expansion [10].

Use of intraoperative ERCP has slowly increased among various endoscopic groups, because the transition of ERCP from the endoscopy unit to the operating room has a short learning curve (endoscopic groups with expertise in preoperative and postoperative ERCP) without the high technical requirements needed by laparoscopic management of the bile duct [12–14].

The aim of this prospective, randomized controlled trial was to compare the efficacy, safety, and surgical outcomes of the intraoperative ERCP plus LC (ERCP + LC), preoperative ERCP + LC and laparoscopic common bile duct exploration (LCBDE) plus LC (LCBDE + LC), and determine the most appropriate approach for patients with choledocholithiasis.

Patients and methods

A prospective, randomized controlled clinical trial was performed to compare 3 treatment options for patients with choledocholithiasis. The study was conducted at the National Center for Minimally Invasive Surgery, Havana, Cuba. This is a tertiary referral university-affiliated center specializing in endoscopic and laparoscopic surgery (Multidisciplinary work group). All the procedures were performed by the 5 authors who are very experienced in both ERCP and laparoscopy. Surgical and endoscopic techniques were standardized before starting the protocol; 2 experienced biliary endoscopists (J.R.T, R.B.Q) performed all ERCP in both groups of patients, while 3 experienced laparoscopic surgeons (J.E.B.G, R.T.P, M.A.M.A) performed LC and LCBDE. The protocol for anesthesia was the same in all patients.

Informed consent was obtained from patients before study participation. The study was approved by our Institution Ethical Committee and by The Cuban Public Registry of Clinical Trials (Unique ID number: RPCECO00000013). The trial was performed in compliance with the Helsinki Declaration and ICH-GCP (efficacy section).

The sample size calculation is as follows: With 3 groups and a binary endpoint (success-failure), we constructed a $3 \times 2$ contingency table. We used the Grizzle, Starmen, and Koch method [15]. The hypotheses tested were:

\[
\begin{align*}
H_0 & : \pi_1 = \pi_2 = \pi_3 \\
H_1 & : \pi_1 \neq \pi_2 \neq \pi_3
\end{align*}
\]

Here $\pi_1, \pi_2, \pi_3$ are the expected success rates in each population group. We employed information from Rochon's paper [16], that is, $p^* = [\pi_1, -\pi_1, \pi_2, -\pi_2, \pi_3, -\pi_3]$ outcomes vector; $\phi(p^*) = [\pi_1, \pi_2, \pi_3]$ (subset of measures of interest); $X$ = Identity matrix of order 3 (design matrix);

\[
C=(1-0 \ 0-1 \ 0-1) ; \ h=0.\ Substitution produced the following formula:
\]

\[
n = \lambda_0 (\pi_1(\pi_1-\pi_2)+\pi_2(\pi_1-\pi_3)+\pi_3(\pi_1-\pi_2)+\pi_1(\pi_2-\pi_3)+\pi_2(\pi_2-\pi_3)+\pi_3(\pi_3-\pi_2)+
\pi_1(\pi_3-\pi_2)+\pi_2(\pi_3-\pi_2)+\pi_3(\pi_3-\pi_2))
\]

where $\lambda_0$ is the non-centrality parameter of the non-central $\chi^2_{2,3,0}$ that satisfies the area lying to the right of the critical point $X^2_{2,1,\alpha}$ is the desired power $1-\beta$ for the design, and where $X^2_{2,1,\alpha}$ represents the $1-\alpha$ percentil of the central $\chi^2$ with 2 degrees of freedom (the number of degrees of freedom is the number of rows of the matrix $C$; $\alpha$ is the significance level of the test); $n$ represents the sample size in each of the three treatment groups.

We chose the values: $\alpha=0.05$, $\beta=0.2$, $\pi_1=0.85$, $\pi_2=0.8$, $\pi_3=0.94$. We get $\lambda_0=9.635$, $n=90$. Assuming a possible 10% of missing data due to protocol violations, we concluded that we should include 100 patients per group, for a total of 300 patients.

The primary endpoint was the rate of success in clearing ductal stones.

From November 2007 to November 2011, 404 patients with suspected CBDs admitted to the hospital were evaluated prospectively for study eligibility. The intake was restricted to appropriate patients [American Society of Anesthesiologists (ASA) I, II and III] in whom choledocholithiasis was suspected on the basis of clinical features (biliary colic with jaundice and recent acute pancreatitis), liver function tests (elevated bilirubin, alkaline phosphatase, gamma-glutamyltranspeptidase), and external ultrasound findings (showing possible CBDs or a dilated common bile duct $\geq 8 \text{ mm}$).

Further exclusion criteria included cholangitis or pancreatitis, age $<18$ years, ASA IV and V, suspected common bile duct (CBD) malignancy, previous cholecystectomy, previous ERCP and/or ES, and contraindications to ERCP or laparoscopic surgery. Moreover, patients treated with total or partial gastric resection were excluded.

After obtaining consent, eligible patients were randomized in 3 treatment groups using computer-generated random number sequences in concealed envelopes with block randomization design.

Group I patients underwent intraoperative cholangiography (IOC) to confirm choledocholithiasis followed by LC associated with intraoperative ERCP, ES and endoscopic stone extraction (ESE). All patients were placed in the usual supine position for LC. LC with IOC was always attempted and images were obtained during this step. ERCP and ES were performed during LC. The surgeon carried out LC without completely dissecting the gallbladder from its bed. This maneuver facilitated ending LC after ERCP, because bowel distention during this procedure limits gallbladder dissection. Besides, in case of ERCP failure, traction of the vesicular bottom facilitated CBD visualization.

We performed a “rendezvous” technique only in those patients, in which endoscopic cannulation of the papilla was difficult (when the papilla is hidden within a diverticulum). We used a guided wire through the cystic duct into the CBD to facilitate bile duct cannulation at subsequent endoscopy.

Group II patients underwent preoperative ERCP, ES with ESE followed by LC (24 to 48 hours later). All patients were placed in prone position.

Group III underwent IOC to confirm the choledocholithiasis followed by LC associated with LCBDE and laparoscopic stone extraction. We performed LCBDE via transcystic, choledochotomy and a few patients underwent flexible choledochoscopy. First, we performed transcystic common bile duct exploration but if a patient had an anomalous anatomy, proximal stones and large or numerous stones, we used choledochotomy for common bile duct exploration. LCBDE via choledochotomy required placement of a T-tube and drain.

We did not use magnetic resonance cholangiopancreatography (MRCP) in our institution.

The following criteria were recorded: success rates (ERCP cannulation rate and surgical success rate), success rates of ductal stone clearance, conversion rates, morbidity (complications were defined as any intraoperative or postoperative (30 days) event that
altered the clinical course such as complications of ERCP including pancreatitis, perforation and bleeding, CBD retained stones, mortality (postoperative mortality was defined as death within 30 days of surgery), total operative time in minutes, and length of hospital stay.

The level of power for the study was set at 80% with a 5% significance level. Categorical variables were compared by X2 test, with Yates correction and the Fisher exact test (two-tailed) when necessary. Continuous variables were compared by the Student t-test or HSD Tukey, depending on distribution. All P values were two-sided. P<0.05 indicated a statistically significant difference. Data were analyzed on an intention-to-treat basis. All calculations were performed by using SPSS, version 21.0.

**Results**

A total of 404 patients with suspected choledocholithiasis were admitted to the National Center for Minimally Invasive Surgery of the Havana Medical University, from November 2007 to November 2011. After excluding 104 ineligible cases (acute cholecystitis, cholangitis, pancreatitis and suspected CBD malignancy), 300 patients were included in the trial and randomized to either group I (Intraoperative ERCP/ES) (n = 99), group II (Preoperative ERCP/ES) (n = 101), or group III (LCBDE) (n = 100). Seven patients had protocol violations (management different from that dictated by random allocation) and 2 had anesthesia complications. As a result, a total of 134 patients were diagnosed with presence of choledocholithiasis and treated during the study period (Fig. 1).

Fig. 1  Clinical outcome of randomized patients.

Table 1 shows the preoperative variables (age, CBD diameter, stone size and stone number) of the three groups.

<table>
<thead>
<tr>
<th>Preoperative variable</th>
<th>Group I (Intraoperative ERCP/ES) n = 99</th>
<th>Group II (Preoperative ERCP/ES) n = 101</th>
<th>Group III (LCBDE) n = 100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58.4 (23–87)</td>
<td>57.7 (20–84)</td>
<td>56.3 (22–87)</td>
</tr>
<tr>
<td>CBD diameter (mm)</td>
<td>8.2 (4–20)</td>
<td>8.4 (5–12)</td>
<td>7.7 (4–20)</td>
</tr>
<tr>
<td>Stone size (6–10 mm)</td>
<td>23 (50.0%)</td>
<td>23 (51.1%)</td>
<td>22 (51.2%)</td>
</tr>
<tr>
<td>Stone number (one stone)</td>
<td>24 (52.2%)</td>
<td>29 (64.4%)</td>
<td>31 (72.1%)</td>
</tr>
</tbody>
</table>

ERCP/ES, endoscopic retrograde cholangiopancreatography plus endoscopic sphincterotomy; LCBDE, laparoscopic common bile duct exploration

Postoperative complications occurred in 6 patients (13.3%) in the preoperative ERCP/ES group; 5 with cholecystitis and 1 with pancreatitis due to ERCP/ES. In the LCBDE group, postoperative complications occurred in 2 patients (4.7%); these patients had bile leak from CBD closure and were treated conservatively with broad-spectrum antibiotics. No postoperative complications were reported in the intraoperative ERCP/ES group. Postoperative complications lasted for a significantly shorter time in the intraoperative ERCP/ES group than in the preoperative ERCP/ES group (P<0.012) (Table 3).

Retained stones occurred in 1 patient (2.2%) in the intraoperative ERCP/ES group and 1 patient (2.3%) in the LCBDE group and were treated with postoperative ERCP. In the preoperative ERCP/ES group, retained stones occurred in 5 patients (11.1%) and were treated with postoperative ERCP.

The rate of retained stones was significantly lower in the intraoperative ERCP/ES and LCBDE groups than in the preoperative ERCP/ES group. There were no significant differences among the groups (Table 4).

Mean operative time was 94.2 minutes (45–300), 9.8 minutes (30–240) and 117 minutes (40–270) for groups I, II and III respectively. Mean duration of the ERCP/ES procedure for groups I and II was 24.7 minutes and 25 minutes, respectively. These
times were significantly shorter than for LCBDE group III (49.7 minutes) \( (P<0.001). \)

There were no deaths or cases of conversion to open surgery. Length of hospital stay was significantly shorter in the intraoperative ERCP/ES group (mean 1.2 days) than in the preoperative ERCP/ES group (mean 3.1 days) \( (P<0.0001) \) and LCBDE group (mean 2.1 days) \( (P<0.012). \)

**Discussion**

Over the past 20 years, LC has become the gold standard for surgical treatment of symptomatic biliary lithiasis, and its development has favored the appearance of a group of new endoscopic/surgical therapeutic possibilities for patients with choledocholithiasis, namely total laparoscopic treatment of choledocholithiasis versus endoscopic treatment using intraoperative ERCP (both single-stage treatments), or preoperative ERCP and postoperative ERCP with LC (2-stage treatment) [6].

Very few studies are available comparing single-stage treatments (LCBDE and intraoperative ERCP) and 2-stage treatment (preoperative ERCP) [6]. Since the introduction of laparoscopic cholecystectomy in our institution in 1993, the standard treatment for CBDs had been preoperative ERCP/ES, followed by LC and postoperative ERCP/ES. With the advance in technology and laparoscopic techniques, we started to perform LCBDE (1995) and intraoperative ERCP/ES (2003), and this randomized trial compares the results among the 3 preoperative approaches. The preoperative and noninvasive tests for predicting CBDs such as clinical examination, history, laboratory tests and ultrasound have a high negative predictive value (92% - 99%). However, the positive predictive value is less satisfactory, and in patients with high suspicion of choledocholithiasis, this is only shown in 13% to 58% of cases. Application of these criteria reveals a high rate of false-positive diagnoses and many unnecessary ERCPs (40% - 50%) [17]. Currently MRCP and endoscopic ultrasound are used routinely before ERCP to prevent unnecessary procedures but they are not available in our institution [5 - 11, 18].

IOC failure occurred at a rate (8%) which is similar to other publications. The single most frequent reason for failure to complete IOC in our series was an inability to cannulate the cystic duct. The success of ERCP cannulation in our study is comparable to IOCs in our series, which allows selective bile duct cannulation and avoids manipulation of the papilla as well as unnecessary injection of contrast material into the pancreatic duct. Early in our work (first 100 intraoperative ERCP/ES in 2003) we tried to pass a guidewire through the cystic duct into the CBD to facilitate bile duct cannulation at subsequent endoscopy (the endo-laparoscopic “rendezvous” described by Cavina et al.) [27] in all cases, but we found it technically difficult and encountered additional difficulties such as...
to bowel insufflations) and the technique’s limitations were related to impacted CBD stones, so we omitted this step in most cases in the clinical trial, as had ElGeidie et al [28], because the endoscopist and team were very experienced with ERCP (more than 10000 ERCP).

Single-stage treatments facilitate performance of LC simultaneously. Recurrent biliary complications are more common in patients who do not have elective cholecystectomy after management of choledocholithiasis by ES [28,29]. When there is a time lag between ERCP/ES and LC, some patients may develop cholecystitis (5%-22%) [30–32]. That difference can be partially explained by the length of the interval between the 2 procedures, which is not well defined, as even in the multicenter trial by the European Association for Endoscopic Surgery (EAES) the interval between endoscopic papillosphincterotomy and LC was not specified [33]. Patients awaiting LC are known to have a high rate of readmission and complications due to acute cholecystitis, pancreatitis, empyema, and cholangitis; others showed that in case of delayed cholecystectomy, performed over 2 weeks after ES, there is a higher conversion rate, increasing from 4% when LC was done within 2 weeks, to 31% between 2 and 6 weeks, and 16% after 6 weeks [34]. Therefore, elective cholecystectomy is indicated 24 to 48 hours after clearance of CBD. Nevertheless, some authors report that it is no possible to know whether the acute inflammation is due to pre-ERCP acute cholecystitis or whether it is induced by ERCP [28].

In our study, a significant amount of local inflammation was found in 5 patients and was associated with pain. We consider that clinically relevant because residual local inflammation in patients after ERCP may negatively affect operative outcomes and necessitate a longer hospital stay. Studies have shown that presence of inflammation as an independent risk factor for bile duct injury during LC [35].

At the time of laparoscopic surgery, bile duct stones can be removed with a straightforward transcystic approach or with technically demanding choledocho-tomy. LCBDE in all candidates offers advantages over preoperative ERCP/ES: equivalent removal of duct stones with fewer procedures, lower cost, and preservation of the biliary sphincter. When laparoscopic bile duct exploration is used, the operation is longer. Consequently, in elderly patients and those with significant comorbidity who may not tolerate longer procedures, the advantage may be lost [36].

Several trials have compared clinical outcomes with the 2-stage approach to those with a single-stage strategy. Rogers and colleagues [36] randomized 122 patients to LC plus LCBDE or to ERCP/ES plus LC. Although the techniques had equivalent efficacy and safety, length of hospitalization was 2 days shorter for those who underwent the combined laparoscopic procedure. Recently, Lu and colleagues [38] performed a meta-analysis of 9 randomized trials that compared 2-stage ERCP and LC with combined LC and bile duct exploration. In 787 patients, the approaches were found to have equivalent efficacy and safety. The longer hospital stay seen in the ERCP group in the individual trials was not evident; however, significantly more procedures were required in the ERCP group than in the combined laparoscopic group. The problem with applicability of these data, however, is that most surgeons are not trained to perform LCBDE.

Bin Wang and colleagues [39] concluded that with regard to stone clearance and overall complication rates, preoperative ERCP is equal to intraoperative ERCP in patients with gallbladder and common bile duct stones. However, intraoperative ERCP is associated with a reduced incidence of ERCP-related pancreatitis and results in a shorter hospital stay. The total hospital stay was significantly shorter with intraoperative ERCP than with preoperative ERCP (RR 2.22, 95% CI 1.98–246; P<0.01). A longer hospital stay was required for preoperative ERCP as a result of management of complications and organization of scheduling slots for preoperative ERCP and LC. Also residual local inflammation in patients after ERCP may negatively affect operative outcomes and demand more length of hospital stay.

Use of intraoperative ERCP has slowly increased among various endoscopic groups [12–14], La Greca et al [14] reviewed all published studies on intraoperative ERCP and found 27 original papers that included between 8 and 96 patients each, thus analyzing a total of 795 patients. The success rate ranged between 69.2% and 100% and averaged 92.3%. The average duration of intraoperative endoscopy was 35 minutes and the average duration of surgery was 104 minutes. The average conversion rate to open surgery was 4.7% and morbidity was 5.1% (0%-19%). Mortality is extremely rare, and from the 27 publications reviewed, only 3 patient deaths were reported, giving rise to a total mortality rate of 0.37%.

The 3 types of treatment are effective and the choice of approach depends on a patient’s particular circumstances and on the experience of the different endoscopic and surgical teams at each center [10].

Conclusions

We conclude that intraoperative ERCP/ES for choledocholithiasis results in a higher rate of choledocholithiasis clearance, shorter hospital stay, and lower morbidity, but further research with a larger study population is necessary to determine the procedure’s additional benefits. Results to date suggests that in appropriate patients, single-stage treatments are the best options.

Competing interests: None

References
7 Hong DF, Xin Y, Chen DW. Comparison of laparoscopic cholecystectomy combined with intraoperative endoscopic sphincterotomy and laparoscopic exploration of the common bile duct for choledocholithiasis. Surg Endosc 2006; 20: 424–427